Market leadership Masimo is a global medical technology leader with a broad portfolio of monitoring technologies, sensors, patient monitors, and connectivity solutions. This positions the company as a trusted partner for hospital systems and clinics seeking advanced noninvasive monitoring capabilities.

Hospital penetration Masimo SET pulse oximetry is used on more than 200 million patients annually and is the primary pulse oximetry at all top U.S. hospitals ranked in the 2025 Newsweek World’s Best Hospitals listing, presenting opportunities for expansions in large health systems and high-end care facilities.

Expansion potential Recent news highlights a potential merger with Danaher, suggesting strategic growth and broader product integration opportunities across Masimo’s monitoring portfolio for larger enterprise deals and cross-sell opportunities in connected care and automation.

Clinical validation Masimo SET has demonstrated strong performance across diverse patient populations, including accuracy across all skin tones in newborns, which can be leveraged to win contracts in pediatric and NICU segments and to differentiate in equity-focused procurement programs.

Strategic partnerships The company’s ongoing evidence generation, investor activity, and demand for innovative monitoring solutions indicate a favorable environment for partnerships with health systems, contract manufacturers, and value-based care initiatives focused on lowering cost of care through noninvasive, reliable monitoring.